Myotonic dystrophy is an inherited disease where a change, called a mutation, has occurred in a gene required for normal muscle function. The mutation prevents the gene from carrying out its function properly. The change is an autosomal dominant mutation, which means one copy of the altered gene is sufficient to cause the disorder. As a result, affected individuals have a 50% chance of passing on the mutated gene to their children. A child is equally likely to have inherited the mutated gene from either parent. If both parents do not have the disease, their children cannot inherit it. Children with congenital myotonic dystrophy almost always inherit the disease from an affected mother.
Genetics
DNA is the genetic material found in the nucleus of nearly every cell. A gene is a stretch of DNA that carries a set of instructions on how a protein should be made. These proteins carry out the functions of the body. Scientists estimate that humans have about 25,000 different genes. For example, there are genes that control eye color, genes that make proteins to break down food in the stomach, and genes that encode enzymes that regulate how cells grow.
When the DNA of a gene is altered, a mutation is said to have occurred. Some mutations have little effect on how the body functions. Others are more serious, causing the production of defective proteins that result in disease symptoms.
Both DM1 and DM2 are passed from parent to child by autosomal dominant mutations. This means that the faulty gene is located on one of the chromosomes that does not determine sex (autosome) and that one copy of the mutated gene is enough to cause the disease (dominant). Because the gene is not located on the X or Y sex chromosomes, it can be passed to male and female children with equal frequency.
In nearly all cases, patients with DM have one normal copy of the DM gene and one copy with the mutation. This means an affected parent has a 50% chance of passing on the mutated gene to an offspring. Individuals who receive the mutated gene will have the disease, although they may not show symptoms for many years. Children that do not inherit the mutated gene will never develop DM.
A recent study suggested that all affected individuals can be traced back to just one or two people who had the original mutations, thousands of years ago. Unlike some genetic diseases (e.g. the types caused by exposure to toxic chemicals or radiation), the mutations causing DM do not occur spontaneously.
Studies have been done to understand how these non-coding mutations could have a trans-dominant effect (i.e. how they could affect other genes not associated with the mutation locus). This research suggests a gain-of-function RNA mechanism underlies the clinical features common to both diseases. In both forms of myotonic dystrophy, RNAs transcribed from the genes have unusually long repeats of either CUG (DM1) or CCUG (DM2). The nucleotide repeats cause the RNA strands to develop abnormal hairpin folds. These mishapen RNA structures then bind splice-regulating proteins, forming RNA-protein complexes that accumulate within nuclei. These nuclear foci can disrupt biological function by altering the available amounts of two classes of RNA-binding splice regulators:
- Musclebind-like (Mbnl) proteins (Mbnl1, Mbnll and Mbxl). Mbnl splice regulators are sequestered in the nuclear foci, resulting in nuclear depletion and a loss of function.
- Cugbp and ETR-3 Like Factors (CELF). The expression of Cugbp1 is increased through a signaling event that results in its phosphorylation and stabilization.
The disruption of these splice regulators interferes with the processing of transcripts in more than twenty other genes. In all cases, the aberrant splicing results in abnormal developmental processing where embryonic isoforms of the resulting proteins are expressed in adult myotonic dystrophy tissues. The immature proteins then appear to cause the clinical features common to both diseases. See examples of affected genes and the resulting clinical features in the chart below.
For a print-ready version of this information click the printer icon below or download a copy of the Myotonic Toolkit.
Myotonic dystrophy is one of the most complex disorders known. In addition to the incredible variability of clinical symptoms, the disease also has unique mechanistic features:
- True autosomal inheritance. The disease phenotype of patients who are homozygous for myotonic dystrophy is essentially the same as those who are heterozygous.
- Variable penetrance. Considerable variability is seen between affected individuals, even within the same family. Somatic mosaicism is common, where the genetic defect can be slightly different in various tissues in a single individual and can change over time.
- Anticipation. The disease symptoms tend to be more severe and occur earlier in successive generations.
- Maternal transmission bias for the congenital form. In the most severe form of myotonic dystrophy (congenital myotonic dystrophy: DM1), transmission is nearly always maternal and does not appear to be related to the severity of the disease in the mother. The mutated gene is only very rarely inherited from the father in newborns with myotonic dystrophy.
For a print-ready version of this information click the printer icon below or download a copy of the Myotonic Toolkit.
Myotonic dystrophy is one of the most complex disorders known. In addition to the incredible variability of clinical symptoms, the disease also has several unique mechanistic features:
- Autosomal dominant inheritance. The genes for DM1 and DM2 are dominant, meaning that a person can inherit the disease even if only one parent carries the gene. Also, a child has the same risk of inheriting DM regardless of whether it is the father or the mother who carries the gene.
- Variable penetrance. This term refers to the fact that the number and severity of DM symptoms varies widely among people with the disease. This is true even among people with the same subtype, and among individuals in the same family.
- Somatic mosaicism. A key characteristic of DM is that different cells in different tissue types will show varying numbers of genetic repeats. This is due at least in part to the fact that the number of repeats changes, is different in different cells and increases in number throughout the lifetime of the individual. Thus, the number of repeats reported in a diagnostic test will depend on how old the individual was when sampled, which tissue was tested and then will only measure the average number of repeats.
- Anticipation. The number of repeats in the DM genes tends to increase with each affected generation. As a result, the symptoms of DM1 appear earlier in life and are more severe in each successive generation. These changes are often dramatic. For example, a person whose only symptom was cataracts that appeared later in life can have a child with life-threatening symptoms present at birth. This effect indicates that the number of times the gene sequence is repeated has a bearing on the severity of the disease symptoms. Anticipation appears to be less pronounced in DM2.
- Transmission of congenital form through mother. The most severe form of myotonic dystrophy (congenital myotonic dystrophy: DM1) is almost always passed to the child from an affected mother. Scientists think that his occurs because the number of repeated sequences expands greatly during the process when the egg cells are created.
Promising Small Molecule Study for DM2
A team of researchers at the University of Illinois at Urbana-Champaign recently published the results of a study in which they designed small molecules to combat myotonic dystrophy type 2 (DM2). Dr. Katharine Hagerman, Research Associate at Stanford University Neuromuscular Division and Clinics, provided MDF with the summary below. The study was published in ChemMedChem.
Previous studies have suggested that the main problem in the cells of people with DM2 is an expansion of a CCTG DNA repeat sequence in the ZNF9 gene. This DNA mutation is transcribed into RNA, where it forms abnormal structures that pull other proteins into clumps and prevent them from performing their normal activities.
In this study, researchers redesigned a small molecule that disrupted the improper interaction of repeat-containing RNA with other proteins, but was highly toxic to cells. Their new molecule still disrupted the desired RNA-protein interaction, but was less toxic and was able to enter cells with greater ease.
Future studies will take the small molecules and test them in fruit flies and mice to see if the molecules will be safe in organisms while continuing to disrupt the RNA-protein interaction associated with DM2. Click here to access the abstract and article.
07/23/2014
DM2 Patients and Statins
A recently released study identifies the gene that may be responsible for increased side effects in DM2 patients taking statins to lower cholesterol. Katharine Hagerman, PhD, Research Associate at Stanford University Neuromuscular Division and Clinics, provides MDF with a summary of the study conducted at the University of Helsinki in Finland.
Abnormal Splicing of NEDD4 in Myotonic Dystrophy Type 2: A Possible Link to Statin Adverse Reactions
Screen M, Jonson PH, Raheem O, Palmio J, Laaksonen R, Lehtimäki T, Sirito M, Krahe R, Hackman P, Udd B.(June 4, 2014).
American Journal of Pathology. e-publication ahead of printing.
A research study headed by Dr. Bjarne Udd at the University of Helsinki recently described biological pathways affected in both myotonic dystrophy type 2 (DM2) and hyperlipidemia (a medical condition most often characterized by high cholesterol or high triglycerides). Previous studies have shown that 63 percent of people with DM2 have high cholesterol, as well as 41 percent of people with DM1. Statins, a class of drugs used to lower cholesterol levels, are commonly prescribed to treat hyperlipidemia, elevated levels of lipid proteins in the blood, as they can block the action of a liver chemical that helps create cholesterol.
One of the side effects of statins is the development of myopathy, including muscle pain, weakness, and cramping. Approximately 5-10 percent of individuals taking statins can develop these symptoms. Individuals with DM have an increased incidence of myopathic side effects when taking statins, and there are many documented cases where statin-induced myopathy is the first muscle symptom experienced in adults eventually diagnosed with DM2.
In order to identify biological pathways that may be affected by both DM2 and statin therapies, these researchers looked at genes that were regulated differently in healthy muscles compared to DM2 muscles and statin-treated muscle cells. They identified a gene, NEDD4, that had increased expression in DM2 (and DM1), and decreased expression in statin-treated individuals with no muscle condition. Furthermore, they showed that the NEDD4 gene was processed differently in DM2 muscles, and made a few different forms of the protein that weren't seen in healthy muscles. The authors suggest that biological pathways involving NEDD4 may be altered in DM, and may be associated with increased statin side effects. According to DM2 research reviews, statins do not have to be avoided. However, if statin treatment produces or amplifies muscle symptoms, there may be other drugs available to combat hyperlipidemia that do not have these side effects in individuals with DM.
07/01/2014
Living with DM2
Dr. Matt Disney and Dr. John Day provide an overview of the DM2 disease mechanism and describe how compounds can be designed as potential therapies for this disease.
Structure of the Myotonic Dystrophy Type 2 RNA
Researchers at important academic labs around the US have recently published exciting new information about advances in DM research. The Matthew Disney Lab at The Scripps Research Institute in Florida announced the results of a study examining RNA toxicity in DM2 patients. Summaries of the studies and results are below, along with links to the PubMed abstracts and complete research publications.
Structure of the Myotonic Dystrophy Type 2 RNA and Designed Small Molecules that Reduce Toxicity Childs-Disney et al (Matthew Disney Lab)
Researchers at Scripps Research Institute in Florida recently examined the structure of the toxic RNA molecule made from the DNA mutation causing myotonic dystrophy type 2 (DM2). Dr. Matthew Disney and his colleagues used a technique called X-ray crystallography to look at the shape of the RNA at the atomic level in order to determine what types of drugs would best attach to it and reduce its toxicity.
One of the reasons the DM2 RNA is unhealthy in cells is because it changes how other genes are processed and regulated. They showed that their custom-designed drugs were able to reverse the improper processing of a gene known to be affected in DM by varying degrees depending on the design of the drug. This study shows that drugs they previously proposed could bind the toxic RNA are now able to be administered to cells with toxic RNA similar to DM2 and reduce the RNA toxicity.
For more information:
Click here to view a pdf of the full article
Click here to read the abstract
01/22/2014